Lipella Pharmaceuticals Inc.
LIPO
$2.52
-$0.005-0.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.20% | -53.99% | 21.29% | -73.00% | 47.95% |
| Total Depreciation and Amortization | 0.00% | -50.00% | 1,300.00% | -85.71% | -30.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -78.73% | 374.25% | -80.45% | -- | -100.00% |
| Change in Net Operating Assets | -10.09% | 763.55% | 89.77% | -1,434.18% | -118.52% |
| Cash from Operations | -51.65% | 28.92% | 33.82% | -90.79% | -5.56% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 122.05% | -- | -100.00% | -87.59% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 122.05% | -- | -100.00% | -87.59% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 397.07% | 118.20% | 22.69% | -234.45% | 225.59% |